MITF knockdown in B16.F10 melanoma cells results in decreased expression of (TLS-promoting) CCL21 and CXCL10 chemokine levels, in association with reduced immune infiltration/inflammation in the TME and enhanced tumor progression (91). This evidence concerns the gene MITF and melanoma.